Cell cycle and no end
暂无分享,去创建一个
[1] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[2] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[3] S. Reed,et al. Deregulated cyclin E induces chromosome instability , 1999, Nature.
[4] K. Sugimachi,et al. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[6] G. Melino,et al. p73: Friend or foe in tumorigenesis , 2002, Nature Reviews Cancer.
[7] M. Molinari. Cell cycle checkpoints and their inactivation in human cancer , 2000, Cell proliferation.
[8] Johannes Gerdes,et al. The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.
[9] J. Gerdes,et al. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[10] M.-H. Lee,et al. Contributions in the domain of cancer research: Review¶Negative regulators of cyclin-dependent kinases and their roles in cancers , 2001, Cellular and Molecular Life Sciences CMLS.
[11] S. Sen,et al. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines , 1997, Oncogene.
[12] K. Vermeulen,et al. Cell cycle and apoptosis , 2003, Cell proliferation.
[13] Su-Jae Lee,et al. Cell cycle and cancer. , 2003, Journal of biochemistry and molecular biology.
[14] M. von Knebel Doeberitz,et al. p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial Neoplasia , 2002, The American journal of surgical pathology.
[15] J. Mandell,et al. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. , 2003, The American journal of pathology.
[16] P. Richardson. Clinical update: proteasome inhibitors in hematologic malignancies. , 2003, Cancer treatment reviews.
[17] A. Yang,et al. On the shoulders of giants: p63, p73 and the rise of p53. , 2002, Trends in genetics : TIG.
[18] J. Gerdes,et al. The Ki-67 protein: fascinating forms and an unknown function. , 2000, Experimental cell research.
[19] G. Hannon,et al. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. , 1994, Nature.
[20] J. Blow,et al. Replication licensing--defining the proliferative state? , 2002, Trends in cell biology.
[21] I. Wong,et al. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.
[22] Y. Shiloh. ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.
[23] C. Roskelley,et al. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer , 2003, Reproductive biology and endocrinology : RB&E.
[24] F. Mertens,et al. Abnormal cell cycle regulation in malignancy. , 1999, American journal of clinical pathology.
[25] G. Peters,et al. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.
[26] Amanda G Paulovich,et al. When Checkpoints Fail , 1997, Cell.
[27] J. Herman,et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.
[28] J. Issa,et al. Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. , 2002, Blood.
[29] D. Johnson,et al. Cyclins and cell cycle checkpoints. , 1999, Annual review of pharmacology and toxicology.
[30] R. Parwaresch,et al. A closer look at the cell cycle , 2005, Virchows Archiv A.
[31] D. Sidransky,et al. p16(MTS-1/CDKN2/INK4a) in cancer progression. , 2001, Experimental cell research.
[32] R. Poon,et al. Cyclin A in cell cycle control and cancer , 2002, Cellular and Molecular Life Sciences CMLS.
[33] R. Wood,et al. Which DNA polymerases are used for DNA-repair in eukaryotes? , 1997, Carcinogenesis.
[34] T. Kelly,et al. Regulation of chromosome replication. , 2000, Annual review of biochemistry.
[35] A. Ganser,et al. Aberrant methylation and impaired expression of the p15INK4b cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML) , 2003, Leukemia.
[36] Jian Kuang,et al. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. , 2002, Molecular biology of the cell.
[37] H. Gali-Muhtasib,et al. Modulating cell cycle: current applications and prospects for future drug development. , 2002, Current cancer drug targets.
[38] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[39] Gregory J. Hannon,et al. pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.
[40] W. Hahn,et al. Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.
[41] Tony Hunter,et al. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.
[42] D O Morgan,et al. Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.
[43] S. Elledge,et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.
[44] C. D. Edwards,et al. A novel p16INK4A transcript. , 1995, Cancer research.
[45] Erich A. Nigg,et al. Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.
[46] D. Altieri. Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.
[47] Stephen J. Elledge,et al. Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.
[48] J. Massagué,et al. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.
[49] F. McKeon,et al. Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. , 2002, Trends in molecular medicine.
[50] G. Hannon,et al. Cloning and characterization of murine p16INK4a and p15INK4b genes. , 1995, Oncogene.
[51] B. Falini,et al. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. , 2002, Blood.
[52] Y. Seo,et al. Prognostic Significance of p21 and p53 Expression in Gastric Cancer , 2003, The Korean journal of internal medicine.
[53] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[54] C. Lillo,et al. The Glial Design of a Teleost Optic Nerve Head Supporting Continuous Growth , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[55] S. Carr,et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway , 1999, Oncogene.
[56] C. Sherr. Cancer Cell Cycles , 1996, Science.
[57] J. Issa,et al. Lack of p21CIP1 DNA methylation in acute lymphocytic leukemia , 2002 .
[58] Sehwan Han,et al. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer , 2003, Journal of surgical oncology.
[59] F. Miller,et al. The cellular basis of tumor progression. , 1998, International review of cytology.
[60] K. Do,et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL) , 2002, Leukemia.
[61] K. Vermeulen,et al. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer , 2003, Cell proliferation.
[62] A. Carnero,et al. Targeting the cell cycle for cancer therapy , 2002, British Journal of Cancer.
[63] R. Douglas,et al. Genetic models in applied physiology: invited review: effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest. , 2003, Journal of applied physiology.
[64] H. Nishitani,et al. Control of DNA replication licensing in a cell cycle , 2002, Genes to cells : devoted to molecular & cellular mechanisms.
[65] James M. Roberts,et al. Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.
[66] J. Scholey,et al. Cell division , 2003, Nature.
[67] J. Hurwitz,et al. Inhibition of Nucleotide Excision Repair by the Cyclin-dependent Kinase Inhibitor p21 (*) , 1995, The Journal of Biological Chemistry.
[68] M. Barbacid,et al. To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.
[69] T. Weinert,et al. Toward maintaining the genome: DNA damage and replication checkpoints. , 2002, Annual review of genetics.
[70] Mong-Hong Lee,et al. Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression* , 2000, The Journal of Biological Chemistry.
[71] K. Isselbacher,et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.
[72] A. Mogilner,et al. Cell division , 2003, Nature.
[73] Isabelle Bedrosian,et al. Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.
[74] J. A. Castillejo,et al. 5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. , 2002, Blood.
[75] L. Chin,et al. The INK4a/ARF locus and melanoma , 2003, Oncogene.
[76] T. Sandal. Molecular aspects of the mammalian cell cycle and cancer. , 2002, The oncologist.
[77] J. Ross,et al. DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. , 1996, Oncology.
[78] J. Bartek,et al. Perspective: defects in cell cycle control and cancer , 1999 .
[79] J F Barrett,et al. Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[80] W. Carroll,et al. c-myc hypermutation in Burkitt's lymphoma. , 1992, Leukemia & lymphoma.
[81] J. Takita,et al. A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma , 2003, Journal of surgical oncology.
[82] Jian Kuang,et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.
[83] Feng Jiang,et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. , 2002, Journal of the National Cancer Institute.
[84] J. Kononen,et al. Cyclin E overexpression and amplification in human tumours , 2003, The Journal of pathology.
[85] N. Rhind,et al. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. , 1997, Science.
[86] Hiroshi Katayama,et al. The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.
[87] J. Lunec,et al. The role of the tumour suppressor p33ING1b in human neoplasia , 2003, Journal of clinical pathology.
[88] C. Schlotter,et al. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer , 2003, Breast Cancer Research.
[89] P. Nurse. A Long Twentieth Century of the Cell Cycle and Beyond , 2000, Cell.
[90] J. Gerdes,et al. The Ki‐67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher‐order chromatin structure , 2002, The Journal of pathology.
[91] S. Tavtigian,et al. Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.
[92] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[93] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[94] A. Venkitaraman. Breast Cancer Genes and DNA Repair , 1999, Science.
[95] J. Cheville,et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.
[96] L. Hartwell,et al. Checkpoints: controls that ensure the order of cell cycle events. , 1989, Science.
[97] Mong-Hong Lee,et al. Regulators of G1 cyclin–dependent kinases and cancers , 2003, Cancer and Metastasis Reviews.
[98] M. J. Ravitz,et al. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. , 1997, Advances in cancer research.
[99] Holly Neibergs,et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 , 2004 .
[100] J. Blow,et al. Replication licensing — Origin licensing: defining the proliferative state? , 2002 .
[101] Brian Schryver,et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.
[102] R. Abraham. Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.
[103] C. Sherr. The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.
[104] E. Harlow,et al. The retinoblastoma tumour suppressor in development and cancer , 2002, Nature Reviews Cancer.
[105] H. Lenz. Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.
[106] R. Weinberg,et al. Control of the cell cycle and apoptosis. , 1999, European journal of cancer.
[107] T. Okamoto,et al. Cdc25C interacts with PCNA at G2/M transition , 2002, Oncogene.
[108] P. Steeg,et al. Cyclins and breast cancer , 2004, Breast Cancer Research and Treatment.
[109] P. Guldberg,et al. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. , 1999, Cancer research.
[110] J. A. Castillejo,et al. CpG island hypermethylation is associated with transcriptional silencing of the p 21 CIP 1 / WAF 1 / SDI 1 gene and confers poor prognosis in acute lymphoblastic leukemia , 2002 .
[111] J. Pietenpol,et al. Cell-cycle dysregulation and anticancer therapy. , 2003, Trends in pharmacological sciences.
[112] H. Mori,et al. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. , 1999, Cancer research.
[113] Carsten Peterson,et al. Predicting the future of breast cancer , 2003, Nature Medicine.